3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
19
Breast Neoplasms
18
Fallopian Tube Neoplasms
13
Neoplasm Metastasis
10
Triple Negative Breast Neoplasms
8
Prostatic Neoplasms
8
Neoplasms
7
Endometrial Neoplasms
7
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Metastatic Castration-resistant Prostate Cancer
4
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
3
Solid Tumors
3
Neuroendocrine Tumors
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Glioma
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Recurrence
2
Pheochromocytoma
2
Paraganglioma
2
Osteosarcoma
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Glioblastoma
2
Ependymoma
2
Interventions
olaparib
1
gallium 68 PSMA-11
1
Pluvicto
1
Gemcitabine
1
Cisplatin
1
Androgen Antagonists
1
Adrenal Cortex Hormones
1
Abiraterone Acetate
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genital Neoplasms, Male
×
olaparib
×
90 days
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled